Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: Exploratory outcomes from a double-blind randomised controlled trial

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1144-1151

  Kampman, Margitta T ^a,b   Steffensen, Linn H ^a,b   Mellgren, Svein I ^a,b   Jørgensen, Lone ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

EDSS; fatigue severity score; grip strength; multiple sclerosis; multiple sclerosis functional composite; RCT; relapse rate; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG; WEIFA KALSIUM; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; DRUG DERIVATIVE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FUNCTIONAL STATUS; GRIP STRENGTH; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; BONE DENSITY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; DISABILITY; DRUG EFFECT; HAND STRENGTH; MIDDLE AGED; NORWAY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RECURRENT DISEASE; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; CHI-SQUARE DISTRIBUTION; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HAND STRENGTH; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NORWAY; PREDICTIVE VALUE OF TESTS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VITAMIN D; YOUNG ADULT;

EID: 84863600623     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511434607     Document Type: Article

References (31)

1. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010 ; 9: 599-612
2. Hanwell HE, Banwell B. Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta. 2011 ; 1812: 202-212
3. Kampman MT, Steffensen LH. The role of vitamin D in multiple sclerosis. J Photochem Photobiol B. 2010 ; 101: 137-141
4. Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 ; 68: 193-203
5. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009 ; 339: b3692
6. Nimitphong H, Holick MF. Vitamin D, neurocognitive functioning and immunocompetence. Curr Opin Clin Nutr Metab Care. 2011 ; 14: 7-14
7. Hoeck AD, Pall ML. Will vitamin D supplementation ameliorate diseases characterized by chronic inflammation and fatigue?. Med Hypotheses. 2011 ; 76: 208-213
8. Steffensen LH, Jorgensen L, Straume B, et al. Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol. 2011 ; 258: 1624-1631
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
11. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005 ; 64: 1144-1151
12. MSFC administration and scoring manual, www.nationalmssociety.org/for- professionals/researchers/clinical-study-measures/msfc/download.aspx?id=259 (accessed 4 November 2011).
13. Lerdal A, Wahl A, Rustoen T, et al. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health. 2005 ; 33: 123-130
14. Grimnes G, Almas B, Eggen AE, et al. Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed. Eur J Endocrinol. 2010 ; 163: 339-348
15. Glad SB, Aarseth JH, Nyland H, et al. Benign multiple sclerosis: a need for a consensus. Acta Neurol Scand Suppl. 2010 ; 122: 44-50
16. Uitdehaag BMJ, Barkhof F, Coyle PK, et al. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin. 2011 ; 27: 1529-1537
17. Tremlett H, Zhao Y, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1368-1374
18. 3 and calcium in multiple sclerosis. Neurology. 2010 ; 74: 1852-1859
19. 3 in multiple sclerosis patients. Immunol Invest. 2011 ; 40: 627-639
20. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011 ; 77: 1611-1618
21. Beauchet O, Annweiler C, Verghese J, et al. Biology of gait control: Vitamin D involvement. Neurology. 2011 ; 76: 1617-1622
22. Ytterberg C, Johansson S, Andersson M, et al. Variations in functioning and disability in multiple sclerosis. A two-year prospective study. J Neurol. 2008 ; 255: 967-973
23. Knippenberg S, Bol Y, Damoiseaux J, et al. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand. 2011 ; 124: 171-175
24. Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011 ; 311: 44-49
25. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011 ; 76: 540-548
26. van der Mei IAF, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007 ; 254: 581-590
27. Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008 ; 14: 1220-1224
28. Weinstock-Guttman B, Zivadinov R, Qu J, et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2010 ; 82: 189-195
29. Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011 ; 76: 1824-1830
30. Simon KC, Munger KL, Kraft P, et al. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol. 2011 ; 258: 1676-1682
31. Greer JM, McCombe PA. Role of gender in multiple sclerosis: Clinical effects and potential molecular mechanisms. J Neuroimmunol. 2011 ; 234: 7-18